🆕🔥State of art review article by 🌟 s
@DrToddLee@syctong
Navigating the Challenges in Staphylococcus aureus Bloodstream Infection: A Practical Guide to Management
"Further subgroup analyses from SNAP will clarify whether the CzIE differentially impacts outcomes with cefazolin versus ASPs. In the meantime, cefazolin should be broadly considered the preferred treatment for most MSSA bacteremia"
Thanks @Inox94 #IDXposts
https://t.co/kuOb4aE9tD
Three antibiotic myths that simply refuse to die — penicillin allergies, the “must finish every dose” rule, and the idea that antibiotics help colds.
New post -- link on next tweet👇
🔥Just published
The GAME CHANGER RCT
Among patients with a hospital-acquired or health-care-associated Gram-negative bloodstream infection, cefiderocol resulted in non-inferior but not superior 14-day mortality compared with standard of care #IDXposts https://t.co/jLWmphItGK
🆕🔥Prospective,multinational PK study by 🌟 @jasonroberts_pk
Meropenem & pip/tazo optimised dosing regimens for critically ill patients receiving RRT
Dosing nomograms developed to inform dosing for different RRT settings, urine outputs & target conc
https://t.co/XgC0GuPaYz
Timeline of chikungunya fever
Typical viral load, symptoms, involved immune cells, and antibody titres during different phases of disease are depicted
https://t.co/pF74oFG6pv
Hi @iPhoOzZ, I just sent you a detailed email response. Thank you for asking this very important question, which affords me the opportunity to offer one of my trademark antibiotic rants. Oooh, feels good, haven't done one of these in a while! Ok...strap in, here we go...
The most anticipated RCT in ID
🔥SNAP RCT🔥The largest RCT 2 date in SA bactermia
N:1341
Cefazolin Vs ASPs ((flu)cloxacillin) for MSSA bacteremia
Cefazolin is non-inferior (90d mortality)& less AKI than ASPs
A practice-changer RCT that must change the guidelines
#ESCMIDGlobal
Why shorter is better
"It's the same efficacy, but safer and with less selection for resistance."
"If you're going to give antibiotics to people who don't need them, at least do us the courtesy of doing it for a brief period of time."
@BradSpellberg
https://t.co/tIZuqWdBqK
Night shifts are associated with a higher risk of death ☠️👇
Here are some evidence based approaches to maintaining healthy while working shifts. A 🧵
(1/x)
Rethinking Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis in Patients with Cirrhosis
➡️Standard of care since the 1990s and is currently recommended by several major GI societies
➡️Weak supporting evidence
➡️No clear mortality benefit
https://t.co/MTTlbofjdk
2024 was a 🔥 year in ID
🆕💫 @CIDJournal @VUMC_ID @JeffFreiberg
What’s Hot This Year in ID Clinical Science
The review highlights some of the most important trials and clinical trends in infectious diseases over the past year #idxposts https://t.co/JqFrv1iSKS
🆕💫 Systematic review @jac_amr
Antibiotic duration for common bacterial infections
Out of 315 studies, 85% concluded equivalence or non-inferiority of shorter courses
Non-inferiority was the most commonly adopted design @BradSpellberg#idxposts https://t.co/JnskIx3WgZ
A potentially useful table for anyone interested in understanding the recommended usage of some of the newer antibacterials, e.g. latest beta-lactam/inhibitor combinations.
#AMR#AMS
🔥🔥 NEW 🔥🔥
Year In Review: Top Infectious Diseases Articles From 2024
Our new post, a great collaboration with my friend
🌟 @IDstewardship
1️⃣6️⃣⚡️🆔 RCTs
@JAMA_current@TheLancet ✨
7️⃣Syst Reviews/Meta
3️⃣🌏Guidelines
@Wiki_Guidelines ✨️
#idxposts
https://t.co/8YWtXqoyrx
A brief tweetorial. The belief that IV is more effective than oral Abx is incorrect. No data to support it. Contrary data to refute it. And it makes no logical sense. The bugs can't know how the abx got there. They only know if enough gets there to inhibit their growth...